Vinorelbine (Navelbine)
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Disease for which it is used
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Hodgkin lymphoma
- Mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Soft tissue sarcoma
- Small cell lung cancer
Patient drug information
- Vinorelbine (Navelbine) patient drug information (Chemocare)[3]
- Vinorelbine (Navelbine) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/23/1994: Initial FDA approval
References
- Drug index
- Chemotherapy
- Intravenous medications
- Vesicant chemotherapy
- Microtubule inhibitors
- Vinca alkaloids
- Breast cancer medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Hodgkin lymphoma medications
- Mesothelioma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Drugs FDA approved in 1994
- WHO Essential Cancer Medicine